Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...
CPE CONSULTANTS, LLC
 

Gastroenteritis in Children


Consent Form

 
You have been invited to participate in a research project titled “Assessing and Improving Pharmacist Knowledge of Pediatric Drug Therapy”. This study is being conducted by Dr. Sharon Ternullo, BS, Pharm.D., Assistant Professor of Pharmacy at The University of Findlay, Brian Lauer and Keith Posendek Pharm.D. candidates at The University of Findlay class of 2015.  This research study is intended for practicing pharmacists licensed in their respective states. If you are not a licensed practicing pharmacist please do not participate in this study.
Volunteer Status
Your participation in this study is completely voluntary and refusal to participate will involve no penalty. You have the right to refuse to answer particular questions. You may elect to withdraw from this study at any time.
 
Purpose
The purpose of this research is to determine and possibly increase the knowledge and perceived competence of licensed pharmacists, as it relates to pediatric drug therapy.
 
Procedure
A pre-assessment questionnaire will be completed to assess prior knowledge of the material. Next the pharmacist will complete a continuing education (CE) lesson. Finally, a post- assessment questionnaire will be completed to analyze the effectiveness of the CE at improving pediatric drug therapy knowledge.
 
Time Commitment
The pre-assessment and post-assessment questionnaires will take between 5 and 15 minutes each. The CE will be one credit hour of ACPE approved CE.
 
Risks
There are no known risks to participating in this research.
 
Benefits
The participant will gain awareness and knowledge regarding pediatric drug therapy. The participant will gain credit for completion of one hour of ACPE approved CE. The participant will help determine if the CE has been beneficial.
 
Payment:
You will not be paid for participating in the study. However, the CE will be provided at no cost to you and will be reported to the National Association of Boards of Pharmacy (NABP) if you provide us with your NABP identification number and birthdate.
 
Confidentiality
Your individual privacy will be maintained in all published and written data resulting from the study. If you withdraw from this study, no further data will be collected but any information that

you have provided may be retained by the researcher and analyzed. All data will be handled using the NABP number that the participant provides. No names or personal information will be used.
 
For Further Information
Any questions, concerns or complaints that you may have about this study, or if you have further questions about your rights as a research subject, you may contact Dr. Sharon Ternullo (faculty advisor), Keith Posendek or Brian Lauer (fifth year pharmacy students) at the following email addresses:
 
 
Additionally, the Chair of the IRB and his/her contact information is provided below. Susan Stevens, Chair
Email: stevenss@findlay.edu Work Phone: 419-434-5442
 
 
I,______________________ (NAME OF SUBJECT) have been adequately informed regarding the risks and benefits of participating in this study. My signature also indicates that I can change my mind and withdraw my consent to participate at any time without penalty.  Any and all questions I had about my participation in this study have been fully answered.  I understand I can keep a copy of this consent form for my records.
 
 
By completing this continuing education program you are consenting to participate in this project and electronically signing that you consent to the above statement. 
 

Fee

$0.00

CE Hours

1.00

CE Units

0.100

Activity Type

  • Knowledge

Target Audience(s)

  • Pharmacists

Accreditation(s)

Accreditation Council for Pharmacy Education
 
The University of Findlay College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of contiuning pharmacy education.

 

 

 

Objectives

  • List the infectious and non-infectious causes of gastroenteritis.
  • Explain the primary prevention methods for gastroenteritis.
  • Describe the difference between the RV1 (Rotarix®) and RV5 (RotaTeq®) rotavirus vaccinations.
  • Describe the appropriate use of antidiarrheals in children for the treatment of diarrhea associated with gastroenteritis.
  • Explain the usefulness of antiemetics for the treatment of vomiting associated with gastroenteritis in children.
  • Explain the therapeutic usefulness of probiotics as adjunct therapy in children for the treatment of gastroenteritis.
  • List the clinical signs and symptoms of dehydration and their association with the severity.
  • Outline the composition of different oral rehydration solutions used as oral rehydration and to prevent dehydration associated with gastroenteritis.
  • Describe dietary considerations and foods or beverages that can exacerbate, treat or prevent dehydration from gastroenteritis.
  • List signs and symptoms that require referral to a physician in a child with gastroenteritis.

Activity Number

0449-0000-14-009-H01-P

Release Date: Mar 17, 2014
Credit Expiration Date: Mar 17, 2017